CDKN2A displayed higher mutation rates across multiple cancer types (31%), and other frequently mutated genes included LRPPRC (13%), PRKAA2 (11%), VLDLR (9%), ASNS (8%), GZMA (7%), GLS (7%), TNFRSF1A (6%), PSAT1 (5%), and PRDX6 (4%). This evidence concerns the gene GZMA and cancer.